INFO SHEET
Linking Antibody to Drug with ThioBridge™ Conjugation Technology for Better ADCs
Antibody-drug conjugates (ADCs) are a powerful approach to targeted cancer treatment, combining monoclonal antibodies (mAbs) with potent drugs. However, first-generation conjugation technologies used in ADC development have limitations such as inconsistent drug-to-antibody ratios (DAR) and unstable linkers. Abzena’s ThioBridge™ conjugation technology offers a solution by providing a more uniform DAR profile, stable linker attachment, and improved pharmacokinetic properties
What's Inside?
Abzena’s ThioBridge™ conjugation technology offers significant advantages for ADC development. It provides a uniform DAR profile, stable linker attachment, and optimized pharmacokinetic properties. Download the info sheet to learn how ThioBridge™ enables precise control over drug loading and attachment sites, supporting efficient production and profiling of ADCs.
Send me the info sheet!
Let's move medicine forward
The asset you’re developing right now can make a real difference for human health. Let us use our wealth of experience to deploy the best technologies, shorten lead times and implement effective risk mitigation strategies.
